Ramet J, Weil-Olivier C, Sedlak W
Universiteit Antwerpen, UZA and Paola Kinderziekenhuis ZNA, Antwerp, Belgium.
Int J Clin Pract. 2005 Nov;59(11):1326-33. doi: 10.1111/j.1742-1241.2005.00647.x.
For the first time, a live attenuated varicella vaccine with an indication for universal vaccination is licensed in all EU countries. It is now time to consider whether in Europe there should be widespread vaccination against varicella to prevent this common and highly infectious disease. Increasing numbers of countries are adopting vaccination programmes against the disease. In those countries where a routine vaccination policy has been adopted, the success of the vaccine has been significant. The USA, which prior to the launch of a universal vaccination programme in 1995 had 4 million cases of varicella per year, has seen a dramatic reduction in varicella morbidity and mortality rates. A universal varicella vaccination policy is an option that needs to be considered for Europe not only in medical terms but also because it would be socially and economically appropriate.
一种具有普遍接种适应症的减毒活水痘疫苗首次在所有欧盟国家获得许可。现在是时候考虑在欧洲是否应该广泛接种水痘疫苗以预防这种常见且传染性很强的疾病了。越来越多的国家正在采用针对该疾病的疫苗接种计划。在那些已经采用常规疫苗接种政策的国家,疫苗取得了显著成效。美国在1995年推出普遍疫苗接种计划之前,每年有400万例水痘病例,如今水痘的发病率和死亡率已大幅下降。普遍的水痘疫苗接种政策不仅在医学方面,而且在社会和经济方面都是合适的,是欧洲需要考虑的一个选项。